☆ 4.1 Meeting Abstract

Glofitamab in Patients with relapsed/refractory (R/R) diffuse large B-Cell Lymphoma (DLBCL) and ≥2 prior Lines of Therapy: Key Results of the Phase-II Expansion

ONCOLOGY RESEARCH AND TREATMENT (2022)

Add to Collection

Journal

ONCOLOGY RESEARCH AND TREATMENT
Volume 45, Issue SUPPL 2, Pages 50-51

Publisher

KARGER

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.